Skip to main content
OpenTrials
Completed

NCT Number: NCT01249092

Pentoxifylline for Primary Biliary Cirrhosis

Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.

Although ursodeoxycholic acid (UDCA) is associated with increased survival in many patients with PBC, there is absence of an adequate response to UDCA in a significant proportion of PBC patients.

Tumor necrosis factor alpha (TNF-alpha) is a cytokine that plays an important role in the pathogenesis of PBC. Other fibrosis biomarkers such as tissue metallo proteinase 1 (TIMP-1) are associated with progression of liver fibrosis in PBC. Pentoxifylline (PTX) is a methylxanthine derivative that inhibits pro-inflammatory cytokines and also has shown anti-fibrotic effects in serum of patients with PBC. Furthermore, PTX has well known clinical and safety profiles. The main hypothesis of this study is that therapy with pentoxifylline (PTX) will result in improvement of liver disease in PBC patients who are incomplete responders to UDCA.

The focus of this proposal is on the effectiveness of PTX in improving laboratory parameters of liver disease and levels of cytokines involved in the pathogenesis of the disease in patients with PBC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Biliary Cirrhosis Bile Duct Diseases Biliary Tract Diseases Cholestasis Cholestasis, Intrahepatic Digestive System Diseases Fibrosis Liver Cirrhosis Liver Cirrhosis, Biliary Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–76 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients ages 18 to 76 years.
  • Established diagnosis of PBC based on at least three of the following criteria:
  • Detectable anti-mitochondrial antibodies (AMA)
  • Cholestatic biochemical pattern
  • Liver biopsy compatible with PBC
  • Appropriate exclusion of other liver diseases.
  • Therapy with UDCA at adequate dose (13-15mg/kg/d) for at least six months and evidence of suboptimal response defined by alkaline phosphatase levels that did not normalize and remain elevated by at least 1.5 times the upper limit of normal.
  • No history or present hepatic decompensation (e.g. variceal hemorrhage, encephalopathy, or poorly controlled ascites).

Exclusion criteria

  • Findings highly suggestive of liver disease of other etiology.
  • A score >=10 points on the Revised Scoring System for autoimmune hepatitis (AIH), supporting a diagnosis of PBC/AIH overlap.
  • Patients on steroids (systemic), immunosuppressants, or immunomodulatory agents within the previous 6 months.
  • Patients with clinical or laboratory evidence suggestive of decompensated cirrhosis.
  • Hypersensitivity to PTX or the methylxanthines (caffeine, theophylline, theobromine).
  • History of cerebral or retinal hemorrhage.
  • Other medical comorbidities (such as cardiac, renal, cancer) that would interfere with completion of the study.
  • Patients taking Theophylline or Coumadin because of potential drug-drug interactions with PTX. In addition, patients taking low molecular weight heparin preparations.
  • Pregnant or nursing women.

Treatment and study plan

Pentoxifylline

Drug

Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.

Primary outcomes

  1. Change in Serum Alkaline Phosphatase Levels.

    Time frame: 6 months

    Serum alkaline phosphatase levels at entry and at 6 months of therapy with PTX will be measured and compared.

Secondary outcomes

  1. Change in Serum Concentration of Tissue Inhibitor Metalloproteinase 1 (TIMP-1) After PTX Therapy.

    Time frame: 6 months

    Serum concentration of tissue inhibitor metalloproteinase 1 (TIMP-1), a fibrosis biomarker of interest, will be measured and the change in serum levels between entry and end of study will be calculated.

  2. Safety of Therapy in the Pilot Study of PTX Therapy in Patients With PBC Will be Assessed

    Time frame: 6 months

    The number of participants that experienced any severe adverse events will be monitored and recorded.

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Registry information

Official study title

A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis

Important dates

Study start
2010
Primary completion
2012
Study completion
2013
First posted
Nov 29, 2010
Registry last updated
Dec 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.